Locally Advanced Malignant Neoplasm
Conditions
Keywords
Pancreas, Pancreatic cancer, Immunotherapy, Chemotherapy, Radiation, Surgery, Pancreaticoduodenectomy
Brief summary
The goal of this study is to evaluate the safety of combination treatment that includes chemotherapy, radiation therapy, and immunotherapy in patients with pancreatic cancer.
Detailed description
This study is for borderline resectable and advanced pancreatic cancer patients. Patients will receive chemotherapy with gemcitabine and immunotherapy with daily tadalafil during the first 21 days of treatment. On study day 22, patients will receive the first of three planned doses of radiation therapy and continue daily tadalafil. Patients are then evaluated to determine if they are candidates for pancreaticoduodenectomy. Patients who are not candidates will continue daily tadalafil and receive gemcitabine chemotherapy. Patients who have surgery will resume daily tadalafil and gemcitabine chemotherapy following recovery from surgery. Patients will receive up to four cycles of gemcitabine.
Interventions
DRUGTadalafil
One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.
DRUGGemcitabine
Three doses of gemcitabine (1000 mg / m\^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.
RADIATIONRadiation
Patients will receive 3 doses of radiation (8-10 Gy per fraction).
PROCEDUREPancreaticoduodenectomy
Surgical resection.
Sponsors
Eli Lilly and Company
Providence Health & Services
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pancreatic adenocarcinoma * Locally advanced unresectable disease, or borderline resectable disease * ECOG (Eastern Cooperative Oncology Group)Performance Status 0 or 1 * Ability to provide consent and comply with study protocol * Women of child-bearing potential must have a negative pregnancy test and avoid pregnancy during the study
Exclusion criteria
* Age \< 18 * History of other malignancy in previous 2 years except carcinoma in situ of the cervix or bladder, or non-melanoma skin cancer * Previous chemotherapy or radiation therapy for pancreatic cancer or previous radiation to the target field * Clinically active autoimmune disease or active infection * History of heart attack within 90 days or stroke within 6 months, hypertension requiring change in blood pressure medications in the last 4 weeks, hypotension, uncontrolled arrhythmias, heart failure (NYHA \>= Class 2 in last 6 months), unstable angina, or angina during sexual activity * Use of nitrates or nitroglycerin * History of hereditary degenerative retinal disorders including retinitis pigmentosa * Chronic systemic corticosteroid use at supra-physiologic doses * Use of recreational drugs called 'poppers' like amyl nitrite and butyl nitrite * Blood test results (neutrophils \< 1000 /uL (microliter); hemoglobin \< 9 gm /dL; platelet count \< 1000 cells / uL; significant coagulopathy; significant liver or renal dysfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 135 Days | Patients will return be seen in the clinic 8 times over the first 50 days for an evaluation of adverse events and toxicities before being evaluated for surgery. Patients who are not candidates for surgery will be seen in clinic 10 more times over the next 85 days for safety evaluations, and patients who have surgery will be seen 10 times over the 85 days following recovery from surgery for safety evaluations. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immune Infiltration in pancreaticoduodenectomy tissue | 50 Days | For surgery patients, formalin fixed and paraffin-embedded tumor tissue obtained during surgery will be sectioned and immunohistology performed to determine the tumor inflammatory micro-environment and the degree of macrophage and T cell inflammation. |
| Quantification of T cells in peripheral blood pre- and post-treatment | 135 Days | Patients will provide a pre-treatment blood sample and 4 blood samples over 135 days to evaluate the influence of the study treatment on immune parameters. For patients who have surgery, the time period will be longer depending on their recovery time. Post-treatment long term follow up will occur every 12 weeks (+/- 2 weeks) beyond post-recovery date (PRD) 85 for 6 visits. Blood will be collected for immune monitoring at each visit. |
Countries
United States
Outcome results
None listed